Massachusetts Financial Services
NRIX icon

Massachusetts Financial Services’s Nurix Therapeutics NRIX Stock Holding History

Massachusetts Financial Services’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Sell
42,603
-1,140
-3% -$18.9K ﹤0.01% 876
2025
Q4 		$830K Sell
43,743
-2,866
-6% -$41.2K ﹤0.01% 838
2025
Q3 		$431K Buy
46,609
+3,065
+7% +$31.8K ﹤0.01% 836
2025
Q2 		$496K Buy
43,544
+538
+1% +$5.81K ﹤0.01% 849
2025
Q1 		$511K Sell
43,006
-24,398
-36% -$408K ﹤0.01% 847
2024
Q4 		$1.27M Sell
67,404
-2,011
-3% -$46.1K ﹤0.01% 798
2024
Q3 		$1.56M Sell
69,415
-28,756
-29% -$651K ﹤0.01% 757
2024
Q2 		$2.05M Sell
98,171
-14,608
-13% -$227K ﹤0.01% 745
2024
Q1 		$1.66M Sell
112,779
-29,367
-21% -$316K ﹤0.01% 747
2023
Q4 		$1.47M Buy
142,146
+101,320
+248% +$694K ﹤0.01% 745
2023
Q3 		$321K Buy
40,826
+20,020
+96% +$183K ﹤0.01% 823
2023
Q2 		$208K Sell
20,806
-490
-2% -$5K ﹤0.01% 812
2023
Q1 		$189K Buy
+21,296
New +$222K ﹤0.01% 835

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Massachusetts Financial Services's NRIX Position: Q1 2026 in Review

Massachusetts Financial Services reduced its Nurix Therapeutics (NRIX) stake by 2.6% in Q1 2026, selling an estimated $18.9K and leaving 42,603 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Massachusetts Financial Services first reported a position in NRIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.05M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Massachusetts Financial Services held 42,603 shares of Nurix Therapeutics worth $660K as of Q1 2026.
  • Massachusetts Financial Services sold 1,140 Nurix Therapeutics shares in Q1 2026, an estimated $18.9K.
  • Nurix Therapeutics made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q1 2026, its #876 holding.
  • Massachusetts Financial Services first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Massachusetts Financial Services's Nurix Therapeutics position peaked at $2.05M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Massachusetts Financial Services's 13F filing for Q1 2026, filed 14 May 2026.